Luis Perez, MD
Family Medicine · Pomona, CANPI 1225099880
Payments from drug & device makers
Across 357 payments — averaging $62.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$15K
- Amgen$1K
- Merz North America, Inc.$810
- Lilly USA, LLC$779
- Novo Nordisk$759
- Abbott$469
- plus $3K from 29 others
What the payments were for
- Speaking & faculty fees$15,28069%
- Food & beverage$6,70130%
- Education$2061%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 11 | $15,413 |
| Amgen | 64 | $1,060 |
| Merz North America, Inc. | 7 | $810 |
| Lilly USA, LLC | 34 | $779 |
| Novo Nordisk | 50 | $759 |
| Abbott | 21 | $469 |
| Astellas Pharma US Inc | 16 | $468 |
| Sanofi-aventis U.S. LLC | 30 | $457 |
| Johnson & Johnson | 27 | $267 |
| Merck | 17 | $263 |
| Pfizer | 15 | $256 |
| Boehringer Ingelheim | 7 | $136 |
| Sunovion Pharmaceuticals Inc. | 8 | $107 |
| Novartis | 6 | $106 |
| E.r. Squibb & Sons, L.L.C. | 6 | $97 |
| GSK | 5 | $92 |
| Sumitomo Pharma America, Inc. | 3 | $82 |
| AstraZeneca(2 entities) | 4 | $69 |
| Alcon | 1 | $59 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $59 |
| Dexcom, Inc. | 3 | $56 |
| Mannkind Corporation | 3 | $39 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Bayer | 2 | $33 |
| Radius Health, Inc. | 1 | $27 |
| Currax Pharmaceuticals LLC | 2 | $26 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Eisai Inc. | 1 | $21 |
| Pfizer Pharmaceuticals LLC | 1 | $20 |
| Nabriva Therapeutics, PLC | 1 | $20 |
| Sanofi | 1 | $17 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Shield Therapeutics Inc | 1 | $16 |
| Lundbeck LLC | 1 | $15 |
| Cequr Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,186 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 166 | $166,478 |
| JanuviaSitagliptin Phosphate | 106 | $87,691 |
| OtezlaApremilast | 12 | $58,966 |
| EliquisApixaban | 70 | $55,120 |
| OzempicSemaglutide | 42 | $43,300 |
| TrulicityDulaglutide | 30 | $39,227 |
| XareltoRivaroxaban | 35 | $31,367 |
| ProliaDenosumab | 15 | $23,423 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $22,603 |
| JanumetSitagliptin Phos/Metformin Hcl | 19 | $19,457 |
| FarxigaDapagliflozin Propanediol | 16 | $14,548 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 35 | $12,341 |
| MyrbetriqMirabegron | 28 | $12,272 |
| LinzessLinaclotide | 18 | $11,869 |
| GemtesaVibegron | 17 | $11,091 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $136 | $176,373185 claims |
| MerckJanuvia, Janumet | $263 | $107,148125 claims |
| AmgenOtezla, Prolia | $1,060 | $82,38927 claims |
| PfizerEliquis | $256 | $55,12070 claims |
| Novo NordiskOzempic | $759 | $43,30042 claims |
| Lilly USA, LLCTrulicity | $779 | $39,22730 claims |
| Johnson & JohnsonXarelto | $267 | $31,36735 claims |
| AstraZenecaFarxiga | $69 | $14,54816 claims |
| Astellas Pharma US IncMyrbetriq | $468 | $12,27228 claims |
| AbbVieLinzess | $15,413 | $11,86918 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $82 | $11,09117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.
Other family medicine in Pomona
- Amit PaliwalPomona$5.5M
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.